What is the ESCUDDO-CVT study?
The ESCUDDO-CVT study is an observational long-term immunological follow-up study of women who received one, two, and three doses of the bivalent vaccine against Human Papilloma Virus (HPV) in the CVT (HPV-16/18 Vaccination Trial Costa Rica – former Guanacaste Epidemiological Project).
ESCUDDO-CVT means: “Long-term immunological follow-up of women who received one, two and three doses of the bivalent HPV vaccine in the CVT (Costa Rica HPV-16/18 vaccination trial): Generating durability data : the “ESCUDDO-CVT” study
Importance of the ESCUDDO-CVT study:
Recently, the World Health Organization (WHO) launched the “Global Strategy to Eliminate Cervical Cancer as a Public Health Problem.” With this, the WHO intends to ensure that all girls in the world are vaccinated against HPV. Also, that all women over the age of 30 be screened and treated; this in case of having precancerous lesions. This study is of the utmost importance since it is part of the complementary research aimed at accelerating the elimination of cervical-uterine cancer as a public health problem.
Importance of the ESCUDDO-CVT study:
To monitor the positivity and stability of the antibodies against HPV 16/18 at a long-term (ie, 14, 16, 18, and 20 years after vaccination) among women vaccinated against HPV by number of doses (ie, 1 dose, 2 doses, and 3 doses).
Design of the ESCUDDO-CVT study:
Principal Investigators of ESCUDDO-CVT Study: Dr. Byron Romero Robles, ACIB-FUNIN and Aimée R. Kreimer, Ph.D, NCI.
Sponsor: National Cancer Institute of United States (NCI), National Institutes of Health (NIH).
Institutions participating in the ESCUDDO-CVT study:National Cancer Institute of United States (NCI), National Institutes of Health (NIH) and Costa Rican Agency for Biomedical Research (ACIB-FUNIN).
Approved by the Scientific Ethics Committee: CEC-HCB-E007-2024
